Tikcro Technologies  has entered into a research and licence agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.

Under the agreement, Tikcro will provide funding for further research at the Weizmann Institute of Science to develop certain antibodies selected and verified in pre- clinical trials. The antibodies may have high selectivity and binding qualities towards cancer immune checkpoints . Further research and development will be required to promote such antibodies as therapeutic candidates for immune modulation in oncology. Tikcro, alone or through sub-licencees, will have the right to obtain the research results and to pursue development through commercialisation.

The licence consideration due from Tikcro to Yeda includes royalties from net sales, sub-license fees and fixed fees linked to clinical and commercial sales milestones.